

Eesti Müeloomiliit
09.06.2016

24. mail esitasime järgmise info:

Palun kirjeldage, kuidas teie esitatud informatsioon patsientide ja/või nende hooldajate kogemuste kohta on kogutud?

Bortezomiibi ja talidomiidi tõhususe näitajad teaduskirjandusest:

- San Miguel, J. F, et al. (2013). Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. *J Clin Oncol*, 31(4), 448-55.
- Mateos, M. V. et al. (2014). GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? *Blood*, 124(12), 1887-93.
- Palumbo, A. et al. (2014). Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. *J Clin Oncol*, 32(7), 634-40.
- Fayers, P. M. et al. (2011). Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. *Blood*, 2118(5), 1239-47.

Lisame eelnimetatutele olulise uuringu, mis kinnitab bortezomiibi oluliselt suuremat kasu võrreldes talidomiidiga:

- Morabito, F. et al. (2014). Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. *Am J of Hematol*. 2014 89(4), 355-362.